Page 11 - Aurobindo Pharma

Aurobindo inks pact to acquire Australian pharma firm for $12.5 mn

Based out of Melbourne, Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Aurobindo Pharma slips 4% post Q2 nos; Credit Suisse, Citi remain bullish

The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.

Aurobindo Pharma reports 21.7 per cent decline in profit, says expenses up

The company was able to improve its US formulations revenues by 6.1 per cent year-on-year at Rs 22.27 billion.

Aurobindo recalls 22 batches of hypertensive drug in US citing cancer risk

According to a notification by the American drug regulator on its website, these 22 batches of Irbesartan drug substance were supplied by the city-based Aurobindo to ScieGen Pharmaceuticals Inc

Aurobindo Pharma scouting for suitable acquisitions in domestic market

Recently, through the acquisition of Sandoz's dermatology and oral solids business, Aurobindo has now entered the branded OTC segment in the US

Aurobindo Pharma buys Sandoz's US business in $900 million deal

The deal gives the Hyderabad based company access to Sandoz's portfolio of oral solids and dermatology drugs and manufacturing footprint

Aurobindo's US operations get growth boost; stock up 9% on Sandoz deal

Attractive valuations, large portfolio add to growth pipeline, keep leverage ratios moderate

Aurobindo Pharma gains 5% on acquisition of Sandoz's US business

The stock rallied 5% to Rs 732 on Thursday, extending its Wednesday's 2% gain on the BSE, after the company announced the acquisition of Sandoz's generic business in the US for $900 million.

Aurobindo Pharma drops plan to buy speciality generics biz of Mallinckrodt

Aurobindo was looking to acquire it for $800 million or so

Growth in key markets perks up Aurobindo stock, earnings to increase

On the flip side, Aurobindo may have seen some pressure on margins led by one-offs as product recall/provisions and some impact on higher raw-material prices

Aurobindo Pharma Q1 net profit slips 12% to Rs 4.5 bn over rising expenses

Total expenses of the company for the first quarter were Rs 37.23 billion, compared to Rs 29.92 billion in the same period last fiscal

Apotex acquisition likely to reduce Aurobindo's dependence on US market

The Apotex acquisition will further strengthen Aurobindo's position among the top 10 pharma companies by sales in Europe

Apotex buy may not initially contribute to Aurobindo's earnings

Unlikely to add to profits in first 2 years; working capital may rise

Aurobindo pharma likely to clinch Mallinckrodt deal for $800 mn this July

Street cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018

Aurobindo Pharma: Nod for niche drugs, strong pipeline to push earnings

Analysts at Elara Capital say Ertapenem approval gives comfort to Aurobindo's ability to grow its US business in FY19, despite the high base

Hyderabad's Aurobindo in race to buy Novartis' generic dermatology business

---- Places a non-binding initial bid of $1.6 bn for the US assets ---- Analysts feel Aurobindo's bid is aggressively placed for low margin assets

US FDA finds 'female mosquito' in Aurobindo Pharma's unit during inspection

FDA also observed that Aurobindo Pharma employees lack the training required to perform their assigned functions

Aurobindo Pharma stock: Good growth in Europe may cushion downside

Analysts said given the strong European prospects and as most concerns relating to unit-IV are priced in, downside was limited for the stock

Aurobindo Pharma receives USFDA observations, say reports; stock falls 5%

The stock dipped 5.4% to Rs 590 on the BSE after the media report suggested that the company received nine observations from the US drug regulator for one of its Hyderabad units.